Table 1.
Clinical characteristics of patients affected with PNS
| Paraneoplastic neurological syndromes | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sex | Age | Neurological syndrome | Antibodies | Malignancy | Time from PNS onset to cancer diagnosis [months] | mRS baseline | mRS one year follow-up |
PNS treatment | |
| F | 57 | Subacute sensorimotor neuropathy | Anti-Ri, anti-myelin | Lung cancer*, # | ( +) 12 | 2 | 3 | IVIG | |
| F | 60 | SSN | Seronegative | Lung cancer* | (−) 6 | 2 | 3 | IVIG | |
| M | 65 | SSN | Anti-Hu, anti-amphiphysin | Lung cancer*, # | (−) 4 | 1 | 1 | Pregabalin | |
| M | 63 | MND° | Seronegative | Lung cancer*, # | (−) 6 | 2 | 2 | No PNS treatment | |
| M | 57 | PCD | Seronegative | Lung cancer*, # | (−) 24 | 1 | 2 | IVIG | |
| F | 56 | SSN | Anti-Hu, anti-amphiphysin | Lung cancer*, # | (−) 1 | 4 | 4 | IVIG | |
| F | 59 | SSN | Anti-Hu | Lung cancer*, # | (−) 24 | 2 | 2 | ||
| M | 57 | PCD | Seronegative | Lung cancer*, # | ( +) 1 | 1 | 1 | IVIG | |
| F | 53 | PCD | Seronegative | Lung cancer*, # | (−) 3 | 3 | 4 | IVIG | |
| M | 71 | PCD | Seronegative | Lung cancer# | (−) 6 | 2 | 3 | IVIG | |
| F | 58 | SSN° | Anti-MAG | Lung cancer# | (−) 24 | 1 | 1 | Pregabalin | |
| M | 73 | Subacute sensorimotor neuropathy | Anti-Ma/Ta, anti-Hu | Lung cancer | (−) 2 | 2 | 2 | IVIG | |
| M | 68 | SSN° | Anti-myelin | Lung cancer# | (−) 6 | 2 | 1 | IVIG | |
| M | 71 | PCD | Seronegative | Lung cancer | (−) 6 | 2 | 3 | IVIG | |
| F | 74 | MND° | Anti-MAG | Lung cancer# | (−) 6 | 2 | 2 | IVIG | |
| M | 64 | Subacute sensorimotor neuropathy° | Seronegative | Lung cancer | ( +) 6 | 1 | 1 | IVIG | |
| F | 72 | Subacute sensorimotor neuropathy° | Seronegative | Lung cancer | (−) 24 | 1 | 1 | IVIG | |
| F | 54 | PCD, SSN | Seronegative | Lung cancer# | (−) 4 | 1 | 2 | IVIG | |
| F | 51 | Myasthenic syndrome | Anti-Hu, anti-myelin | Lung cancer | ( +) 9 | 2 | 3 | Plasma exchange | |
| F | 72 | SSN | Anti-Hu | Lung cancer | (−) 3 | 1 | 0 | IVIG | |
| M | 82 | Subacute sensorimotor neuropathy° | Seronegative | Lung cancer# | (−) 4 | 2 | 1 | Pregabalin | |
| F | 60 | PCD | Anti-Ri, anti-amphiphysin, anti-Ma/Ta | Ovarian cancer# | (−) 8 | 2 | 2 | IVIG | |
| F | 62 | SSN° | Seronegative | Ovarian cancer# | (−) 3 | 2 | 1 | Pregabalin | |
| F | 59 | PCD | Seronegative | Ovarian cancer | (−) 6 | 3 | 2 | IVIG | |
| F | 48 | SSN | Anti-amphiphysin | Ovarian cancer# | (−) 3 | 2 | 1 | IVIG | |
| F | 62 | PCD | Anti-Yo | Ovarian cancer# | (−) 1 | 3 | 3 | IVIG | |
| M | 76 | MND, SSN | Seronegative | Prostate cancer | (−) 6 | 3 | 6 | IVIG | |
| M | 86 | SSN | Seronegative | Prostate cancer | ( +) 3 | 1 | 1 | Pregabalin | |
| F | 57 | SSN | Anti-Yo | No tumor | N/A | 2 | 1 | Pregabalin | |
| M | 73 | Myopathy, subacute sensorimotor neuropathy | Anti-Ma/Ta, anti-Ri, anti-amphiphysin, anti-myelin | No tumor | N/A | 1 | 1 | Pregabalin | |
In the column “Time from PNS onset to cancer diagnosis [months]” (−)—indicates that PNS preceded malignancy diagnosis, ( +)—indicates that PNS symptoms developed after cancer diagnosis
MND motor neuron disease, PCD paraneoplastic cerebellar degeneration (subacute cerebellar degeneration), SSN subacute sensory neuronopathy
*Small cell lung cancer, #previous treatment with chemotherapy, °‘Possible’ PNS (based on Graus criteria) [6], mRS the Modified Rankin Scale, N/A not applicable